by Brook White | Apr 7, 2020 | Posters
Presented at AD/PD Meeting April 2-5, 2020 Virtual Conference Regulatory agencies are increasingly focused on measures of meaningful functional improvement to assess the outcome of symptomatic and disease modifying therapies. The Virtual Reality Functional Capacity...
by Brook White | Apr 7, 2020 | Blog
Social distancing requirements based on COVID-19 have left many sponsors looking for alternatives to in-person study visits for both on-going clinical trials and clinical trials planning to start soon. As we’ve been having conversations with sponsors about their...
by Brook White | Apr 3, 2020 | Blog
The COVID-19 pandemic and associated social distancing measures are creating unprecedented challenges for everyone working in clinical trials and drug development. In this series, we’re sharing some of the ways VeraSci is addressing these challenges. With many...
by Brook White | Apr 1, 2020 | Press Releases
This week, Nature Medicine published results from an innovative trial in anhedonia. Anhedonia, or lack of pleasure, is a key symptom in a number of mood and anxiety disorders including depression. VeraSci experts Dr. Rich Keefe, CEO, and Trina Walker, VP Clinical...
by Brook White | Mar 31, 2020 | Blog
Multiple sclerosis is a complex disease that presents numerous challenges in selecting appropriate measurements for a given clinical trial. These challenges can include: Handling inflammation and relapses versus degeneration and progression A lack of understanding in...
